- 2026
-
Press releases - 16.06.2026
CLOVES Syndrome : European Medicines Agency grants marketing authorisation for alpelisib
Aalpelisib has now been approved by the European Medicines Agency for the treatment of severe forms of PIK3CA-related overgrowth spectrum (PROS), including CLOVES syndrome. This therapeutic breakthrough is the result of the work carried out by Professor Guillaume Canaud and his team within the Translational Medicine and Targeted Therapies Unit at Université Paris Cité, Necker-Enfants Malades Hospital AP-HP, and Inserm.
-
Press releases - 15.06.2026
Scientists have succeeded in creating larger intestinal organoids with a functional nervous system
More and more people are suffering from gastrointestinal diseases. To better understand these conditions and provide solutions for patients, scientists are working on organoids, small three-dimensional biological structures capable of replicating certain functions of an organ. These models are valuable tools for studying cell development and disease mechanisms. A team from Inserm and the University of Nantes, in collaboration with American teams, has developed a new culture method that, for the first time, enables the production of large, functional human intestinal organoids and does so twice as fast as existing methods.
-
Press releases - 10.06.2026
From precancerous lesions to colorectal cancer: shedding light on unexpected biological mechanisms
The prevention of colorectal cancer relies on the early detection and removal of precancerous lesions, which can significantly reduce the risk of progression to invasive cancer. However, the immune mechanisms involved in these lesions remain poorly understood. A research team from Inserm, Sorbonne University, and Paris Cité University has identified an association between immune activity in the microenvironment of precancerous lesions, the frequency of polyp development, and the risk of colorectal cancer.
-
Press releases - 21.05.2026
Food colourings and preservatives: Three new studies point to links between food additives and an increased risk of cancer, type 2 diabetes, cardiovascular disease, and hypertension
Among the 3.5 million food and beverage items listed in the Open Food Facts World database in 2024, more than 139,000 contain at least one food colouring additive and more than 700,000 contain at least one preservative. Three new studies show links between the consumption of these additives and an increased risk of cancer, type 2 diabetes, cardiovascular disease, and hypertension. This research is conducted by a team of researchers from Inserm, INRAE, Sorbonne Paris Nord University, Paris Cité University, and the CNAM, within the Nutritional Epidemiology Research Team (CRESS-EREN).
-
Press releases - 04.05.2026
Démangeaisons et inflammation de la peau : l’implication étonnante de nos neurones
Les troubles dermatologiques sont caractérisés par une inflammation et des démangeaisons sévères, et les traiter ainsi que les soulager représentent un véritable défi pour la recherche. Une équipe de l’Inserm, du CNRS et de l’Université de Toulouse, a montré que dans la dermatite de contact, deux catégories de nocicepteurs avaient des fonctions biologiques distinctes. En effet, l’une permettrait de réguler les démangeaisons, tandis que l’autre semble agir directement sur l’inflammation provoquée par certains troubles dermatologiques.
-
Press releases - 30.04.2026
Intra-tumour immunotherapy: mobilising the immune system against cancer while avoiding toxicity to the body
Published in the journal Nature, the NIVIPIT study, led by Gustave Roussy and conducted by researchers from Inserm and the University of Paris-Saclay, demonstrates the benefit — in terms of both efficacy and safety — of administering an immunotherapy treatment intratumorally that is typically given intravenously. This approach, carried out via interventional radiology — a field in which Gustave Roussy is a leading actor — involves injecting the treatment directly into the patient’s tumour to increase its effectiveness while limiting side effects
-
Press releases - 27.04.2026
Pancreatic cancer: an antibody proves itself in an early clinical trial
Pancreatic cancer, which affects a growing number of patients, remains one of the most aggressive forms due to the ability of cancer cells to resist traditional treatments such as chemotherapy.
-
Press releases - 24.04.2026
A major international clinical trial sheds new light on a paediatric brain cancer
BIOMEDE 1.0, sponsored and coordinated by Gustave Roussy, is the largest clinical trial ever conducted in diffuse intrinsic pontine glioma, an aggressive paediatric cancer in which survival rarely exceeds one year. The findings, published in the journal Nature Medicine, chart a new biological map of the disease, identify patient response biomarkers, and document the prolonged survival of four children — opening concrete avenues for the therapies of tomorrow. This study was led principally by a team of researchers from Inserm, the Université Evry Paris-Saclay, the Université Paris-Saclay, and Gustave Roussy.
-
Press releases - 22.04.2026
Using fewer cosmetics quickly reduce exposure to certain chemical pollutants and endocrine disruptors, such as bisphenol A
Using fewer cosmetics and skincare products can quickly reduce exposure to several chemicals, including known or suspected endocrine disruptors, according to a study published on April 7 in Environment International by researchers from Inserm, the University of Grenoble Alpes, and the CNRS, at the Institute for the Advancement of Biosciences, and supported by the European Commission.
-
Press releases - 05.03.2026
Alzheimer’s: discovery of the involvement of new cells in the onset and progression of the disease
Patients with Alzheimer’s disease have common biological alterations, including abnormal accumulation of the Tau protein in the brain. The mechanisms behind this abnormality may be on the verge of being elucidated. In a new study, a research team from Inserm, the University of Lille, and Lille University Hospital has revealed for the first time the role of tanycytes in the equation.